MELI vs NBIX · P/E 43, rev $19.01B vs P/E 45, rev $1.77B
MercadoLibre Inc. (MELI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MELI revenue for 2026-06-30 was $19.01B. Net income was $883.0M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MELI currently screens at market cap $82.73B and trailing P/E 43.1. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MELI and NBIX stock pages for the full models.
Not investment advice.